Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT). Note: The request metadata references "Altery Therapeutics Ltd," but the filing text explicitly identifies the registrant as Prana Biotechnology Limited.
Reporting Period: April 2014 (Specifically April 7, 2014).
Filing Type: Form 6-K (Report of Foreign Private Issuer) containing an ASX Appendix 3B (New Issue Announcement) and Cleansing Statement.
Business Activity: The company is a biotechnology entity focused on clinical development and research programs, specifically advancing its lead compound, PBT2.
Key Financial Metrics and Capital Structure
Capital Raised: Approximately AUD $16,378,781.
Securities Issued:
- Ordinary Shares: 59,171,610 new shares issued.
- Options: 1,200,000 unlisted options issued under the Employee Share Option Plan (ESOP).
Issue Price: AUD $0.3578 per share (for shares issued under Listing Rule 7.1A).
Post-Issue Capital: 488,646,960 Ordinary Shares quoted on ASX.
Costs: Broker commission fee of 3% of funds raised. No underwriting fees were incurred.
Financial Performance: The filing does not provide revenue, profit, cash flow, or margin data. It is a capital raising announcement, not a financial results report.
Material Changes vs. Prior Period
Share Capital Increase: The company increased its issued share capital by approximately 12.3% (from ~481.7 million to ~488.6 million shares) through the issuance of 59,171,610 new shares.
Placement Capacity Utilization:
- Rule 7.1 (15% Capacity): Fully utilized. Remaining capacity is 0.
- Rule 7.1A (10% Capacity): 6,914,938 shares issued under this rule. Remaining capacity is 34,974,803 shares.
Dilution: Existing shareholders not participating in the issue now hold 98.58% of the post-issue capital, while new shareholders under Rule 7.1A hold 1.42%.
Guidance, Outlook, and Management Commentary
Use of Proceeds: Funds are designated to fund current clinical development, research programs, and working capital. Specifically, the company aims to accelerate the regulatory pathway of its key clinical asset, PBT2.
Financing Strategy: Management intends to continue utilizing a variety of financing options, including capital raisings, government grants, private grants, tax rebate programs, licensing agreements, and the "At The Market" (ATM) facility in the US.
Reasoning for Issue Type: The company utilized the ATM facility and Listing Rule 7.1A due to cost and timing benefits compared to other issue types.
Risks and Contingencies: The filing includes a Cleansing Statement under Section 708A(5) of the Corporations Act, confirming compliance with disclosure laws and stating there is no "excluded information" required to be disclosed.
Investor Verification Checklist
- Verify the total number of shares on issue (488,646,960) against the company's latest registry.
- Confirm the remaining placement capacity under ASX Listing Rule 7.1A (34,974,803 shares) to assess future dilution risk.
- Review the terms of the 1,200,000 new ESOP options (Exercise Price: AUD $0.25; Expiry: April 6, 2018).
- Monitor the progress of the PBT2 clinical asset to ensure funds are being deployed as stated.
- Check for any subsequent filings regarding the utilization of the US ATM facility.